Treatments Compared for Advanced Renal Cell Carcinoma
Treatment-free survival more than twice as long for nivolumab plus ipilimumab versus sunitinib for intermediate/poor-risk patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.